ABOS
NASDAQ · Biotechnology
Acumen Pharmaceuticals Inc
$2.36
+0.17 (+7.76%)
Financial Highlights (FY 2025)
Revenue
32.13M
Net Income
3.79M
Gross Margin
40.3%
Profit Margin
11.8%
Rev Growth
+20.9%
D/E Ratio
0.36
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 40.3% | 40.3% | 40.3% |
| Operating Margin | 12.3% | 11.3% | 11.9% |
| Profit Margin | 11.8% | 12.2% | 10.6% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.13M | 32.40M | 26.28M |
| Gross Profit | 12.94M | 13.05M | 10.58M |
| Operating Income | 3.95M | 3.67M | 3.14M |
| Net Income | 3.79M | 3.97M | 2.79M |
| Gross Margin | 40.3% | 40.3% | 40.3% |
| Operating Margin | 12.3% | 11.3% | 11.9% |
| Profit Margin | 11.8% | 12.2% | 10.6% |
| Rev Growth | +20.9% | +8.5% | +2.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 32.08M | 34.90M | 32.16M |
| Total Equity | 88.26M | 100.56M | 90.94M |
| D/E Ratio | 0.36 | 0.35 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.50M | 6.39M | 4.32M |
| Free Cash Flow | 1.86M | 2.43M | 2.61M |